| Literature DB >> 32683595 |
Kavitha Shettigar1,2, Thokur Sreepathy Murali3.
Abstract
Foot ulcer is a common complication in diabetic subjects and infection of these wounds contributes to increased rates of morbidity and mortality. Diabetic foot infections are caused by a multitude of microbes and Staphylococcus aureus, a major nosocomial and community-associated pathogen, significantly contributes to wound infections as well. Staphylococcus aureus is also the primary pathogen commonly associated with diabetic foot osteomyelitis and can cause chronic and recurrent bone infections. The virulence capability of the pathogen and host immune factors can determine the occurrence and progression of S. aureus infection. Pathogen-related factors include complexity of bacterial structure and functional characteristics that provide metabolic and adhesive properties to overcome host immune response. Even though, virulence markers and toxins of S. aureus are broadly similar in different wound models, certain distinguishing features can be observed in diabetic foot infection. Specific clonal lineages and virulence factors such as TSST-1, leukocidins, enterotoxins, and exfoliatins play a significant role in determining wound outcomes. In this review, we describe the role of specific virulence determinants and clonal lineages of S. aureus that influence wound colonization and infection with special reference to diabetic foot infections.Entities:
Keywords: Clonal diversity; Diabetic foot; Infection; Osteomyelitis; Staphylococcus aureus; Toxins; Virulence
Mesh:
Substances:
Year: 2020 PMID: 32683595 PMCID: PMC7669779 DOI: 10.1007/s10096-020-03984-8
Source DB: PubMed Journal: Eur J Clin Microbiol Infect Dis ISSN: 0934-9723 Impact factor: 3.267
S. aureus virulence factors involved in wound progression
| Virulence factors | Function | Role in infection | References |
|---|---|---|---|
| MSCRAMMs | |||
| Bone sialoprotein-binding protein (isoform of SdrE) (Bbp) | Adhesion to extracellular matrix, bone and joint tissue, fibrinogen | Osteomyelitis | [ |
| Cap5 and Cap8 | Inhibits interaction between C3b, immunoglobulin and receptors; targets phagocytes; promotes virulence in | Mastitis, cystic fibrosis, endocarditis | [ |
| Collagen adhesin (Cna) | Collagen-binding adhesin mediates binding to cartilage/ collagen-rich tissue, blocks complement activation | Osteomyelitis, septic arthritis, keratitis | [ |
| Fibronectin-binding proteins A (FnBPA) and B (FnBPB) | FnBPA binds to fibrinogen and elastin; FnBPB binds to fibronectin; adhesion to ECM | Endocarditis, implant orthopaedic infections, osteomyelits, arthritis | [ |
| Iron-regulated surface determinant protein H (IsdH) | Haem uptake and iron acquisition into bacterial cytoplasm | SSTI | [ |
| Serine–aspartate repeat-containing protein D (SdrD) | Binds desquamated epithelial cells; nasal colonization | Bone infection | [ |
| SdrE | Binds complement factor H; evades immune response; degrades C3b | SSTI | [ |
| Bone sialoprotein-binding protein (isoform of SdrE) | SD-rich fibrinogen-binding, bone sialoprotein-binding protein | Osteomyelitis, arthritis | [ |
| Toxins/superantigens | |||
| Epidermal cell differentiation inhibitor (Edin) | Inhibits actin cytoskeleton of epithelial and endothelial barrier; formation of large transcellular tunnels; targets host Rho proteins; inhibits complement-mediated phagocytosis | Bacteremia | [ |
| LukDE | Kills leukocytes and macrophages via chemokine receptors | Dermonecrosis | [ |
| PVL | Targets complement receptors C5aR and C5L2, apoptosis of neutrophils, necrosis | Necrotizing pneumonia, SSTI, furunculosis | [ |
Fig. 1Schematic diagram illustrating major S. aureus factors associated with DFI and DFOM. (Adapted from Kong et al. [13]). ACME, arginine catabolic mobile element; agr, accessory gene regulator; Bbp, bone sialoprotein-binding protein; CC, clonal complexes; Cna, collagen adhesin; FnBP, fibronectin-binding protein; MSCRAMMs, microbial surface components recognizing adhesive matrix molecules; PMT complex, PSM transporter complex; PSM, phenol-soluble modulins; PVL, Panton-Valentine leukocidin; SAgs, super antigens; sarA, staphylococcal accessory regulator; sae, response regulator; SdrD, serine–aspartate repeat-containing protein D; SEs, staphylococcal enterotoxins; SspA, staphylococcal serine protease; SspB, cysteine protease; TSST-1, toxic shock syndrome toxin-1
Clonal lineages and associated virulence markers of S. aureus in skin and wound infection
| Source of sample | Major virulent factors/major findings | Prevalent genotype | Reference |
|---|---|---|---|
| SSTI | pvl | ST152, ST121, ST5, ST15, ST1, ST8, and ST88 | [ |
| SSTI, surgery infection, bone and joint infection, and others | CapH5, capJ5, capK5 | CC5, CC8, CC97 | [ |
| capH8, capI8, capJ8, and capK8 | CC45 | ||
| egc cluster | CC5, CC45 | ||
| Absence of fnbB | ST228-I | ||
| Cna | ST239-III and ST45-IV | ||
| SSTI | hla | ST239 | [ |
| Impetigo | eta | CC15, CC9, and ST88 (CC88) | [ |
| eta, etb | ST121 | ||
| Wound, urine, semen | egc | CC5, CC25, CC30, CC45, CC121 | [ |
| etd | CC25, CC80 | ||
| edinB | CC25, CC80, CC152 | ||
| Wounds, nares, blood, sputum, urine, and others | egc cluster | CC5, CC22, CC30, and CC228 | [ |
| sed, sej, ser | CC8 | ||
| Tst1 | CC5, CC30 | ||
| Wound and respiratory samples | PVL | ST80-MRSA-IVc | [ |
| Bone and joint infections | ACME | CC8-MSSA | [ |
| EtD, edinB | CC25, CC80 | ||
| capH8, capI8, capJ8, capK8 | CC7, CC12, CC15, CC30, CC45, CC59, ST80, CC88, ST96, CC101, CC121, ST239 and ST426 | ||
| cna | CC12, CC22, CC30, CC45, CC96, CC121, ST239, and ST426 | ||
| sasG ( | CC5, CC8, CC15, CC22, ST49, CC59, ST80, CC88, and ST96 | ||
| Invasive infections | Egc | CC5, CC25, CC30, and CC45 | [ |
| Tst | CC30 | ||
| Etd | CC25 | ||
| Invasive infections | Tst--1 | CC30/CC39 | [ |
| SSTI, respiratory tract infections, osteomyelitis | Hla, psmα, RNAIII | ST59 | [ |
| sasX (cell wall-anchored protein) | ST239-MRSA-SCCmecIII-t037 | ||
| Nasal swabs | Increased biofilm production at 0%, 0.1%, and 0.25% glucose concentrations | CC8 | [ |
| Higher mortality rate; PSMα3 peptide variant with reduced immune-stimulatory and cytolytic activity | CC30 | [ | |
| Osteo-articular infection | CC22 | [ | |
| Community settings | agr-I | CC59 | [ |
| Community settings | PVL | ST1153-MSSA | [ |
| Community, multiple clinical settings | pvl | ST1, ST5, ST8, ST22, ST30, ST80, ST772, ST452, ST59, ST93, CC121, and ST154 | [ |
| pvl negative | ST239 | [ | |
| Hospital settings | Tn6072 | ST239 | [ |
| Hospitalized patients at risk of MRSA carriage | cna | CC1, 12, 22, 30, 45, 51, and 239 | [ |
| TSST-1 | CC30 | ||
| Multiple clinical samples | High level of Hla production | CC1, CC5, CC8, CC15, or CC96 | [ |
| Complete absence of Hla production | CC22, CC30, CC45, CC479, CC705 |